293 related articles for article (PubMed ID: 9442107)
1. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.
Muñoz-Barroso I; Durell S; Sakaguchi K; Appella E; Blumenthal R
J Cell Biol; 1998 Jan; 140(2):315-23. PubMed ID: 9442107
[TBL] [Abstract][Full Text] [Related]
2. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.
Kliger Y; Gallo SA; Peisajovich SG; Munoz-Barroso I; Avkin S; Blumenthal R; Shai Y
J Biol Chem; 2001 Jan; 276(2):1391-7. PubMed ID: 11027678
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
Lawless MK; Barney S; Guthrie KI; Bucy TB; Petteway SR; Merutka G
Biochemistry; 1996 Oct; 35(42):13697-708. PubMed ID: 8885850
[TBL] [Abstract][Full Text] [Related]
4. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
Bär S; Alizon M
J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
[TBL] [Abstract][Full Text] [Related]
5. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
Rimsky LT; Shugars DC; Matthews TJ
J Virol; 1998 Feb; 72(2):986-93. PubMed ID: 9444991
[TBL] [Abstract][Full Text] [Related]
6. gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.
Marcon L; Sodroski J
J Virol; 1994 Mar; 68(3):1977-82. PubMed ID: 8107258
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
9. The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells.
Golding H; Manischewitz J; Vujcic L; Blumenthal R; Dimitrov DS
J Virol; 1994 Mar; 68(3):1962-9. PubMed ID: 7906314
[TBL] [Abstract][Full Text] [Related]
10. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
11. Initial stages of HIV-1 envelope glycoprotein-mediated cell fusion monitored by a new assay based on redistribution of fluorescent dyes.
Dimitrov DS; Golding H; Blumenthal R
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):799-805. PubMed ID: 1742075
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
[TBL] [Abstract][Full Text] [Related]
13. Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events.
Blanco J; Barretina J; Ferri KF; Jacotot E; Gutiérrez A; Armand-Ugón M; Cabrera C; Kroemer G; Clotet B; Esté JA
Virology; 2003 Jan; 305(2):318-29. PubMed ID: 12573577
[TBL] [Abstract][Full Text] [Related]
14. Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.
Litwin V; Nagashima KA; Ryder AM; Chang CH; Carver JM; Olson WC; Alizon M; Hasel KW; Maddon PJ; Allaway GP
J Virol; 1996 Sep; 70(9):6437-41. PubMed ID: 8709277
[TBL] [Abstract][Full Text] [Related]
15. The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41.
Xu Y; Zhang X; Matsuoka M; Hattori T
FEBS Lett; 2000 Dec; 487(2):185-8. PubMed ID: 11150506
[TBL] [Abstract][Full Text] [Related]
16. Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41.
Shugars DC; Wild CT; Greenwell TK; Matthews TJ
J Virol; 1996 May; 70(5):2982-91. PubMed ID: 8627774
[TBL] [Abstract][Full Text] [Related]
17. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
18. Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178.
Wexler-Cohen Y; Johnson BT; Puri A; Blumenthal R; Shai Y
J Biol Chem; 2006 Apr; 281(14):9005-10. PubMed ID: 16455666
[TBL] [Abstract][Full Text] [Related]
19. Capture of an early fusion-active conformation of HIV-1 gp41.
Furuta RA; Wild CT; Weng Y; Weiss CD
Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
[TBL] [Abstract][Full Text] [Related]
20. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
